Krystal Biotech, Inc. (KRYS)
341.78
-4.80
(-1.39%)
USD |
NASDAQ |
Aug 24, 16:00
341.78
0.00 (0.00%)
After-Hours: 20:00
Krystal Biotech Enterprise Value : 9.421B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 9.421B |
| August 20, 2026 | 9.138B |
| August 19, 2026 | 9.325B |
| August 18, 2026 | 9.013B |
| August 17, 2026 | 9.099B |
| August 14, 2026 | 8.997B |
| August 13, 2026 | 8.881B |
| August 12, 2026 | 9.015B |
| August 11, 2026 | 8.843B |
| August 10, 2026 | 8.977B |
| August 07, 2026 | 8.825B |
| August 06, 2026 | 8.714B |
| August 05, 2026 | 8.805B |
| August 04, 2026 | 8.775B |
| August 03, 2026 | 8.414B |
| July 31, 2026 | 9.259B |
| July 30, 2026 | 10.02B |
| July 29, 2026 | 9.915B |
| July 28, 2026 | 9.943B |
| July 27, 2026 | 9.576B |
| July 24, 2026 | 9.084B |
| July 23, 2026 | 8.856B |
| July 22, 2026 | 9.131B |
| July 21, 2026 | 9.198B |
| July 20, 2026 | 9.203B |
| Date | Value |
|---|---|
| July 17, 2026 | 9.666B |
| July 16, 2026 | 9.279B |
| July 15, 2026 | 9.529B |
| July 14, 2026 | 9.209B |
| July 13, 2026 | 9.920B |
| July 10, 2026 | 9.990B |
| July 09, 2026 | 10.15B |
| July 08, 2026 | 10.27B |
| July 07, 2026 | 10.07B |
| July 06, 2026 | 10.25B |
| July 02, 2026 | 10.26B |
| July 01, 2026 | 10.16B |
| June 30, 2026 | 10.16B |
| June 29, 2026 | 10.32B |
| June 26, 2026 | 10.14B |
| June 25, 2026 | 9.781B |
| June 24, 2026 | 9.419B |
| June 23, 2026 | 9.200B |
| June 22, 2026 | 9.295B |
| June 18, 2026 | 9.432B |
| June 17, 2026 | 9.243B |
| June 16, 2026 | 8.705B |
| June 15, 2026 | 8.745B |
| June 12, 2026 | 8.546B |
| June 11, 2026 | 8.651B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Marker Therapeutics, Inc. | 11.25M |
| TG Therapeutics, Inc. | 8.510B |
| Tenaya Therapeutics, Inc. | 82.22M |
| Cytokinetics, Inc. | 10.76B |
| Vericel Corp. | 2.116B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 54.77M |
| Revenue (Quarterly) | 119.22M |
| Total Expenses (Quarterly) | 64.45M |
| EPS Diluted (Quarterly) | 1.786 |
| Gross Profit Margin (Quarterly) | 93.46% |
| Profit Margin (Quarterly) | 45.94% |
| Earnings Yield | 2.33% |
| Operating Earnings Yield | 1.91% |
| Normalized Earnings Yield | 2.335 |